Vijay Shreedhar - Jun 21, 2021 Form 4 Insider Report for Adamas Pharmaceuticals Inc (ADMS)

Role
Chief Commercial Officer
Signature
/s/ Christopher B. Prentiss, Attorney-in-fact
Stock symbol
ADMS
Transactions as of
Jun 21, 2021
Transactions value $
-$31,983
Form type
4
Date filed
6/23/2021, 04:09 PM
Next filing
Nov 24, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADMS Common Stock Sale -$32K -6.2K -3.61% $5.16 166K Jun 21, 2021 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the mandatory sale to cover withholding tax requirements of the issuer's equity incentive plan, the shares were sold to cover the tax obligation realized upon the vesting of restricted stock units.
F2 Represents the weighted average sale price for the entire number of shares sold. The shares were sold at prices ranging from $5.10 to $5.20. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Includes 2,500 shares acquired under the issuer's employee stock purchase plan on May 28, 2021.